Digital Health & Discovery Platform
@dhdp-ca.bsky.social did:plc:w6uj7tqg2364o3cs23opmtia
We combine Canadian expertise in artificial intelligence (AI) and precision medicine to improve healthcare for Canadians. www.dhdp.ca Led by the Terry Fox Research Institute @terryfoxresearch.bsky.social
Bei Bluesky seit
- Follower
- 156
- Folgt
- 363
- Posts
- 405
- Tage in Ranglisten
- 0
Zusammenfassung
Digital Health & Discovery Platform (@dhdp-ca.bsky.social) ist seit 21 April 2025 auf Bluesky. Das Konto hat 156 Follower, folgt 363 Konten und hat 405 Posts veröffentlicht.
Ranglisten-Platzierungen
Die besten Tage, an denen Posts dieses Kontos in Debyas Tagesliste kamen.
Dieses Konto war noch in keiner Tagesrangliste.
Zuletzt gelikte Posts
Öffentliche Likes aus dem Bluesky-Netzwerk.
HAPPENING NOW: Fueling Digital Health Innovation How can a $25M gift accelerate cancer research through AI, machine learning and big data? Charles Crosbie of the Terry Fox Research Institute explores how this investment can advance innovation across Canada’s public and private sectors. #PACT2026
Post anzeigen🍁 Investing in future precision onocology leaders 🍁 MOHCCN is awarding $2.1 million to four outstanding early-career clinician-scientists through the 2026 Clinician-Scientist Awards. Read the full announcement: www.marathonofhopecancercentres.ca/impact/news-...
Post anzeigenIs treatment working? Could it come back? For young people with Hodgkin lymphoma, uncertainty can be overwhelming. Dr. Tomohiro Aoki, a 2026 MOHCCN Clinician-Scientist Awardee, is developing a blood test to monitor treatment response and detect relapse earlier. Learn more: tinyurl.com/eskd7r68
Post anzeigenThe immune system is designed to fight disease. So why can some brain tumours evade its attack? Dr. Charles Couturier, a neurosurgeon and researcher at McGill University, is working to find answers with support from a 2026 MOHCCN Clinician-Scientist Award. Learn more: tinyurl.com/5cvr3m5e
Post anzeigenHow do we know when a more advanced treatment is the better choice? 2026 MOHCCN Clinician-Scientist Awardee, Dr. Rachel Glicksman will lead the ASPIRE clinical trial to assess whether adaptive SBRT improves patients’ quality of life and if it's cost-effective. Learn more: tinyurl.com/3zwarwen
Post anzeigen
Blockierte Konten
Blockierungen sind auf Bluesky öffentlich.
Dieses Konto blockiert niemanden.